XGenCloud. Cloud service intended for automatic interpretation of genetic tests results, allows to form detailed genetic conclusion. Cloud service intended.

Slides:



Advertisements
Similar presentations
Lecture 2 Strachan and Read Chapter 13
Advertisements

HTA Consulting 11 years experience Our proposal for European Countries
VUS: The clinician’s view Mary Porteous On behalf of Scottish Clinical Geneticists.
By Zircon Infotech. View today’s patient’s appointment Appointments given to new patient immediately Give appointment to patient on further dates Cancellation.
Genetic research designs in the real world Vishwajit L Nimgaonkar MD, PhD University of Pittsburgh
Pavel Tarlykov, PhD General Genetics LTD Astana, Kazakhstan Raleigh, 2014.
Introduction to Research Methodology
Direct to Consumer Testing Issues. Types of tests being sold Diagnostic tests – identify specific conditions Carrier testing - identify those who carry.
Dr. Almut Nebel Dept. of Human Genetics University of the Witwatersrand Johannesburg South Africa Significance of SNPs for human disease.
Copyright © McGraw-Hill Education. Permission required for reproduction or display. Chapter 14 Constant Allele Frequencies.
The Pursuit of Better Medicines through Genetic Research Terri Arledge, DVM US Department Head Drug Development Genetics.
Human Genetics Overview.
Case reports Sadeghi Ramin, MD Nuclear Medicine Research Center, Mashhad University of Medical Sciences.
Evolutionary Change in Populations: Population Genetics, Selection & Drift.
Genetic Counseling & Genetic Testing Katelyn Meadows & Betty Hagerman.
Seminar Assignment HT Seminar assignment Handed out at course start Group work / individual assessment Research based aspects, requires independent.
Bulgaria “How to make a business plan”. The business plan is written document describing the nature of the business, the sales and marketing strategy,
IDENTIFICATION AND CONSULTATION WITH DATA USERS – TANZANIA EXPERIENCE Presentated by Irenius Ruyobya National Bureau of Statistics Tanzania September,
Role of clinical genetics in medicine. Who provides this service Varies depending on structure and funding of service but is in reality provided by many.
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Blueprint of Life Topic 9: Pedigrees
Copyright © 2010 Pearson Education, Inc. publishing as Benjamin Cummings Lectures by Greg Podgorski, Utah State University Diet Advice From DNA? Current.
Unit 1: The Language of Science  communicate and apply scientific information extracted from various sources (3.B)  evaluate models according to their.
ASH SPECIALIST PROGRAM REPORT Thomas D. Giles, MD, President of the ASH Specialist Program Inc.,
Standardization of Pedigree Collection. Genetics of Alzheimer’s Disease Alzheimer’s Disease Gene 1 Gene 2 Environmental Factor 1 Environmental Factor.
Development of Bioinformatics and its application on Biotechnology
Marketing Research: Overview
Introduction to Precision Medicine
Clinical causality assessment I. Ralph Edwards R.H.B Meyboom.
Introduction to BST775: Statistical Methods for Genetic Analysis I Course master: Degui Zhi, Ph.D. Assistant professor Section on Statistical Genetics.
The Use of Pharmacoeoconomics and Pharmacoepidemiology in Your Local MTF P&T Process by Marv Shepherd, Ph.D. Jim Wilson, Ph.D. Center for Pharmacoeconomic.
Chapter 13 Carrier Screening. Introduction Carrier screening involves testing of individuals for heterozygosity for genes that would produce significant.
Pattern of Diabetes Emergencies among adult Yemeni Diabetic Patients Dr. Zayed Atef Faculty of Medicine Sana’a University.
14 Population Genetics and Evolution. Population Genetics Population genetics involves the application of genetic principles to entire populations of.
Scenario Paul is rushed into intensive care where a diagnosis of acute myocardial infarction (heart attack) is made. His cholesterol level is 325mg%,
Paris Project Meeting January 2012 Item – Statistics Objective 5 B. Proia With financial support from Criminal Justice Programme 2008 European Commission.
Clinical Pharmacy Part 2
Care and PreventionResearch Programme > Responses to health risk information; Risk type, controllability and the role of the self L. Claassen 1, L. Henneman.
Apo E and pharmacogenetics: tailoring cures to the patient Jose Ordovas PhD Professor/Senior Scientist JM-USDA-Human Nutrition Research Center on Aging,
10/22/2015 AER Social Politics & Public Health Committee 2, Katowice ( Slaskie, PL ) A REVIEW OF THE HEALTH SYSTEM IN ROMANIA
Prospective Evaluation of B-type Natriuretic Peptide Concentrations and the Risk of Type 2 Diabetes in Women B.M. Everett, N. Cook, D.I. Chasman, M.C.
Risk Management & Corporate Governance 1. What is Risk?  Risk arises from uncertainty; but all uncertainties do not carry risk.  Possibility of an unfavorable.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
EXPERIMENTAL EPIDEMIOLOGY
بسم الله الرحمن الرحيم جامعة أم درمان الإسلامية كلية الطب و العلوم الصحية - قسم طب المجتمع مساق البحث العلمي / الدفعة 21 Basics of Clinical Trials.
Polymorphisms in the CRP and C1 Q genes and schizophrenia in Armenian population: A pilot study Zakharyan R 1,2, Khoyetsyan A 1, Chavushyan A 1, Arakelyan.
The Marketing Research Process and Proposals Copyright © 2010 by the McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin.
RESEARCH METHODS IN TOURISM Nicos Rodosthenous PhD 07/02/ /2/20131Dr Nicos Rodosthenous.
Inherited Thrombophilia Testing as Observed at a Reference Laboratory Brian Jackson, MD, MS Medical Director of Informatics.
Association of functional polymorphisms of Bax and Bcl2 genes with schizophrenia Kristina Pirumya, PhD, Laboratory of Human Genomics and Immunomics Institute.
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2.
Computational Biology and Genomics at Boston College Biology Gabor T. Marth Department of Biology, Boston College
Research Methods in Psychology Introduction to Psychology.
LOGO REPORT WRITING Presented By TEHMINA FARRUKH LECTURER BSD.
GENETIC MARKERS OF CORONARY ARTERY DISEASE RISK GALYA ATANASOVA MD, PhD DOMINIC JAMES.
Monday, June 23, 2008Slide 1 KSU Females prospective on Maternity Services in PHC Maternity Services in Primary Health Care Centers : The Females Perception.
NABEEL BONDAGJI, MD, FRCSC CONSULTANT PERINATOLOGIST KFSH&RC - JEDDAH “CONTRACEPTION IN WOMEN WITH MEDICAL DISORDERS”
Ethics in Clinical Genetics and Genomics Key Knowledge Year 4 Medical Ethics and Law Thread Course, The Ethox Centre, University of Oxford.
Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
 Professional liability insurance to 3rd celebrations is merely inside just like misdeed; even if the insurance policy can't.
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Technology of healthcare  BY: seemeka Johnson. Technology of healthcare Doctors now know that genetics play a part in possibly passing on diseases from.
Report Writing Lecturer: Mrs Shadha Abbas جامعة كربلاء كلية العلوم الطبية التطبيقية قسم الصحة البيئية University of Kerbala College of Applied Medical.
Department of Biological and Medical Physics
Prescribing.
Genetic Testing Result Means. Before Genetic Testing  The result of genetic testing can be life changing.  It is important for patients and their families.
Epidemiology 101 Epidemiology is the study of the distribution and determinants of health-related states in populations Study design is a key component.
Kandeke C, Chibuta C, Banda D
Presentation transcript:

xGenCloud

Cloud service intended for automatic interpretation of genetic tests results, allows to form detailed genetic conclusion. Cloud service intended for automatic interpretation of genetic tests results, allows to form detailed genetic conclusion. Authors and developers: Igor Ugarov, MD, PhD xGenCloud

Business model I NEEDS OF CLIENTS WHICH WILL BE PROVIDED BY SERVICE 1.Automatic formation of the individual list of necessary genetic analyses for the patient depended on his (her) phenotype, family history, drug consumption, and environmental factors. 2.Automatic interpretation of genetic tests results and formation of detailed genetic conclusion. xGenCloud

Business model II 1.Increasing of sales volume of genetic analyses; 2.Decreasing of expenses for clinical geneticist in staff of clients business; 3.Development of such modern and perspective field of knowledge as predictive (personalized) medicine allows clients business to remain competitive; 4.Increasing of sales volume of all other services offered by medical center (medical consultations by doctors of various specialties, other laboratory tests, and instrument investigations) – this will be provided by including special recommendations in every genetic conclusion for the purpose of prevention of this or that complex disorder. ADVANTAGES OF USING xGenCloud SERVICE FOR BUSINESS OF CLIENTS: xGenCloud

PRICE POLICY: Monthly fee 1. Payment for automatic formation of list of required genetic tests. 2. Packages of certain number of interpretations of genetic tests results. It is also possible to pay for each interpretation * The price is depended on number of tested genes (polymorphisms). xGenCloud Business model III

SCENARIO OF SERVICE USING: Medical consultation of patient by the doctor of certain medical center (hospital). ↓ Using service xGenCloud during consultation the doctor gets individual list of genetic tests (genes and polymorphisms) which should be done for the patient depending on phenotype, family history, drug consumption, and environmental factors (all these factors need to be entered into the software). ↓ According to the list of administered genetic tests patient sample is analyzed by any genetic laboratory. ↓ After receiving genetic results the doctor enters results into the software xGenCloud and gets automatically generated detailed genetic conclusion which explains him what kind of genetic predisposition his patient has and what should be done to prevent the disease. ↓ Finally patient receives text file with genetic conclusion which includes individualized recommendations regarding supervision and examination by certain doctors, also list of additional laboratory tests and instrument investigations which should be carried out to decrease risk of the disease. As a result patient continues to attend medical center (hospital) on regular basis. xGenCloud Business model IV

POTENTIAL CLIENTS: - Genetics laboratories - Medical-genetic consultations - Research institutes - Medical centers offering genetic testing:  Hospitals (centers) of reproduction  Centers of anti-age medicine  Sanatoriums  Other The system is intended to help doctors of various specialties who consult patients with common disorders (multifactor diseases), allows to test patients for genetic predisposition correctly and to receive automatically generated conclusion by results of genetic testing. MARKETING STRATEGY xGenCloud

ADVANTAGES BASIC ADVANTAGES OF xGenCloud AGAINST COMPETITORS:  Complex data analysis  Using of possible data maximum  The most extensive database  Constant updating of the service  More than 10 years experience in the field of development of software for medical genetics of software for medical genetics  More than 5 years experience in the field of predictive medicine  The volume of interpretations is not limited (service can provide as much interpretations as clients business needs) interpretations as clients business needs) xGenCloud

- Catalog of signs includes terms and allows to describe in detail phenotype of the patient. Catalog of diseases which intended to describe family history includes more than 3000 nosological forms. - More than 2000 pharmacological drugs are included in the medicines catalog. All drugs are in terms of INN (international nonproprietary names) which allows to define medicine exactly and to consider its active components. - Catalog of environmental factors allows to consider habits, life-style of the patient, and influence of various exogenous factors on development of multifactor diseases. - Catalog of genes gives information about genes, 6000 genes are described with their associations with different diseases. - Use of gene networks allows to consider interaction between genes in algorithm of selection for DNA diagnostics. DESCRIPTION I xGenCloud

Program based on platform xGen IDS xGen IDS which is registered in the State register of programs № May 07, 2008 DESCRIPTION II xGenCloud

EXAMPLES I Examples of input of phenotype signs, family history, and prescribed medicines xGenCloud

Result of genes selection in the form of list after entering certain parameters EXAMPLES II xGenCloud

Catalog of gene networks (example of searching for gene network of an acute nonlymphocytic leukemia) EXAMPLES III xGenCloud

Catalog of genetic associations EXAMPLES IV xGenCloud

AUTOMATICALLY GENERATED GENETIC CONCLUSION 1. Introduction (short description of genetic testing carried out for the patient); 2. Table with results of genetic analyses (genes, rs, genotype, etc); 3. List of practical recommendations regarding prevention of diseases to which genetic predisposition is revealed; 4. Scientific explanation of interpretation of genetic results: 4.1 Short description of all analyzed genes and their polymorphisms; 4.1 Short description of all analyzed genes and their polymorphisms; 4.2 Frequency of revealed genotypes in population; 4.2 Frequency of revealed genotypes in population; 4.3 Terminological dictionary; 4.3 Terminological dictionary; 4.4 References. 4.4 References. TEXT FILE WHICH CONSISTS : xGenCloud

EXAMPLE of INTERPRETATION (fragment of short description of gene) Cardiovascular system: F2 Gene F2 is localized on the 11 th chromosome (11p11-q12) and encodes factor of coagulation II – prothrombin. It is one of key factors of blood clotting. The most significant and discussed in literature polymorphism of DNA in F2 gene is G20210A. Polymorphism is situated in 3’ untranslated region of the gene and influences at mRNA level leading to increasing of prothrombin concentration in blood plasma. However among heterozygous carriers of risk allele prothrombin level varies very much, therefore simple quantitative analysis of this marker in blood can't be used for diagnostics of prothrombin thrombophilia. Result: Polymorphism G20210A is not found (genotype G/G). Frequency of allele 20210A in European population is ~3 %. Found genotype is prevailing in population. Prothrombin is one of the main components of coagulative system of blood. At the first stage of process of coagulation prothrombin turns in thrombin by photolytic cleavage and finally promotes formation of fibrin in blood clotting process. Presence of risk allele in F2 gene is characterized by increased level of prothrombin in blood and is associated with increased relative risk of development of thrombosis and as a consequence with increased risk of myocardial infarction and ischemic stroke. Conclusion: In gene F2 requied polymorphism which increases risk of thrombosis isn't found. xGenCloud

Authors and developers: Igor Ugarov, MD, PhD